Your browser doesn't support javascript.
loading
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
Xu, Binghe; Zhang, Qingyuan; Hu, Xichun; Li, Qing; Sun, Tao; Li, Wei; Ouyang, Quchang; Wang, Jingfen; Tong, Zhongsheng; Yan, Min; Li, Huiping; Zeng, Xiaohua; Shan, Changping; Wang, Xian; Yan, Xi; Zhang, Jian; Zhang, Yue; Wang, Jiani; Zhang, Liang; Lin, Ying; Feng, Jifeng; Chen, Qianjun; Huang, Jian; Zhang, Lu; Yang, Lisong; Tian, Ying; Shang, Hongyan.
Affiliation
  • Xu B; Department of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Cener/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Zhang Q; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150000, China.
  • Hu X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
  • Li Q; Department of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Cener/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Sun T; Department of Galactophore, Liaoning Cancer Hospital & Institute, Shenyang 110801, China.
  • Li W; Department of Oncology, the First Hospital of Jilin University, Changchun 130061, China.
  • Ouyang Q; Department of Galactophore, Hunan Cancer Hospital, Changsha 410000, China.
  • Wang J; Department of Galactophore, Linyi Cancer Hospital, Linyi 276000, China.
  • Tong Z; Department of Breast Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300000, China.
  • Yan M; Department of Breast Disease, Henan Breast Cancer Center, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
  • Li H; Department of Breast Oncology, Beijing Cancer Hospital, Beijing 100000, China.
  • Zeng X; Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing 400000, China.
  • Shan C; Department of Breast and Thyroid Oncology, Affiliated Hospital of Jining Medical University, Changchun 130021, China.
  • Wang X; Department of Medical Oncology, Run Run Shaw Hospital, Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
  • Yan X; Department of Head and Heck Oncology, West China Hospital, Sichuan University, Chengdu 610000, China.
  • Zhang J; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
  • Zhang Y; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150000, China.
  • Wang J; Department of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Cener/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Zhang L; Department of Galactophore, Liaoning Cancer Hospital & Institute, Shenyang 110801, China.
  • Lin Y; Department of Thyroid & Breast Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China.
  • Feng J; Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing 210000, China.
  • Chen Q; Department of Galactophore, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou 510000, China.
  • Huang J; Department of Oncological Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
  • Zhang L; Taizhou EOC Pharma Co., Ltd., Taizhou 318000, China.
  • Yang L; Taizhou EOC Pharma Co., Ltd., Taizhou 318000, China.
  • Tian Y; Taizhou EOC Pharma Co., Ltd., Taizhou 318000, China.
  • Shang H; Taizhou EOC Pharma Co., Ltd., Taizhou 318000, China.
Acta Pharm Sin B ; 13(5): 2250-2258, 2023 May.
Article in En | MEDLINE | ID: mdl-37250148
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Acta Pharm Sin B Year: 2023 Document type: Article Affiliation country: China Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Acta Pharm Sin B Year: 2023 Document type: Article Affiliation country: China Country of publication: Netherlands